Sinobioway Medicine(SZ:002581) Qi Lu Wan Bao Wang·2025-07-18 11:25Group 1 - The capital market is experiencing a chain reaction, with Shandong Weiming Pharmaceutical Co., Ltd. (referred to as "Weiming Pharmaceutical") announcing significant stock price fluctuations and risk warnings due to abnormal trading activity [1] - Weiming Pharmaceutical expects a net loss attributable to shareholders of 55 million to 85 million yuan for the first half of 2025, representing a year-on-year decline of 85.72% to 187.02% [1] - The crisis is primarily due to the suspension of production and sales by its core subsidiary, Tianjin Weiming Biological Pharmaceutical Co., Ltd. (referred to as "Tianjin Weiming"), following a failure to meet GMP compliance requirements [1] Group 2 - Tianjin Weiming's production and sales of interferon drugs are the main source of revenue for Weiming Pharmaceutical, contributing 60% of the company's revenue in 2024 [2] - In 2024, Tianjin Weiming reported an operating income of 216 million yuan and a net loss of 14.0037 million yuan, significantly impacting Weiming Pharmaceutical's consolidated financial performance [2] - As of now, there are two A-share listed companies in Zibo under other risk warnings (ST), including Weiming Pharmaceutical and Shandong Lianchuang Industrial Development Group Co., Ltd. (referred to as "Lianchuang Shares") [2]